Skip to main content

Abstract

Objectives:

This study sought to examine psychiatrists’ perceptions of gaps in the availability of mental health and substance use services and their ability to spend sufficient time and provide enough visits to meet patients’ clinical needs.

Methods:

A cross-sectional probability survey of U.S. psychiatrists was fielded during September through December 2013 by using practice-based research methods, including distribution by priority mail. Psychiatrists (N=2,800) were randomly selected from the American Medical Association Physician Masterfile, and 1,188 of the 2,615 (45%) with deliverable addresses responded. Of those, 93% (N=1,099) reported currently treating psychiatric patients, forming the sample for this study.

Results:

Thirty percent or more of psychiatrists reported being unable to provide or find a source for each of the following services in the past 30 days: psychotherapy, housing, supported employment, case management or assertive community treatment, and substance use treatment. Approximately 20% reported being unable to provide or find a source for inpatient treatment, psychosocial rehabilitation, general medical care, pharmacologic treatment, and child and adolescent treatment. Approximately half (52%) of psychiatrists reported not having enough time during patient visits, affecting 28% of patients. More than one-third (37%) reported being unable to provide enough visits to meet patients’ clinical needs, affecting 24% of patients.

Conclusions:

Psychiatrists reported constrained availability of a range of mental health, substance use, and general medical services. In order for the Affordable Care Act to realize the promise of increased access to care, the infrastructure for mental health and substance use treatment, workforce, and services delivery may require significant enhancement.
The expansion of Medicaid and implementation of health insurance exchanges (HIEs) under the Affordable Care Act (ACA), which took effect January 1, 2014, was expected to produce substantial increases in demand for mental health and substance use services. An estimated 52 million individuals have gained mental health insurance coverage since then (1), including 35 million individuals who gained mental health coverage through the parity protections extended to individual and small-group insurance markets (2). These newly insured populations are expected to have higher rates of mental health and substance use treatment needs compared with the population in general (3).
For policy and services planning purposes, it will be important to monitor access to mental health and substance use treatment services to quantify potential workforce and treatment supply constraints and needs. Such constraints may result in limited access to services for newly insured patients. Because a broad range of evidence-based treatments has been shown to be effective in managing mental and addictive disorders and to significantly decrease the illness burden (4), ensuring access to these services is consequential. Although the ACA is designed to improve access to treatment by expanding insurance coverage, improving services delivery models, and promoting payment and other quality improvement and health information technology reforms, the extent to which the nation’s health care systems will be able to meet the expected increase in demand for services—particularly for individuals with mental and substance use disorders—is unclear.
Extensive research has examined specific factors affecting mental health treatment access and identified barriers to care, including attitudinal, financial, and structural barriers (58). Studies that have sought to quantify problems related to treatment access have used different methodologies, including epidemiologic studies and claims analyses. Studies of treatment availability have primarily used waiting lists and analyses of disproportionate geographic distribution of the mental health workforce and of treatment facilities. Findings from these studies have consistently documented treatment access and availability problems for individuals with mental and substance use disorders (916).
This study was designed to complement prior research by examining systematically collected data from a large probability sample of U.S. psychiatrists to assess their perceptions of mental health treatment availability and accessibility in 2013, the year before implementation of the ACA Medicaid expansions and HIEs. Understanding and documenting treatment gaps are important for policy and services delivery planning to highlight constraints in the availability of specific services and to help ensure that individuals with mental illnesses receive needed treatments.
The primary aims of this study were to assess psychiatrists’ perceptions of the availability of specific treatments and services for mental and substance use disorders and of their ability to spend enough time with patients and provide a sufficient number of visits to meet patients’ clinical needs. The study also identified sociodemographic and practice attributes of psychiatrists who were more likely to report treatment access problems.

Methods

This study used data collected from the Study of Psychiatric Practice Under Health Care Reform, a large probability sample of psychiatrists in the United States. This study was fielded from September through December 2013, before the January 1, 2014, implementation of the ACA insurance expansions. A total of 2,800 physicians who self-identified as psychiatrists and who had not been randomly selected for participation in a survey conducted by the American Psychiatric Association in the past 24 months were randomly selected from the September 2013 release of the Physician Masterfile of the American Medical Association (AMA). Physicians were excluded if they resided outside the United States, if they were psychiatry residents, and if direct patient care was not listed as their type of practice. Persons with undeliverable addresses, who were deceased, or who were incorrectly identified in the AMA Masterfile as psychiatrists (N=185) were excluded. Responses were obtained from 1,188 of the 2,615 psychiatrists in the remaining sample (45%). Of those, 89 were no longer practicing psychiatry or were no longer involved in direct patient care, resulting in a final study population of 1,099 self-identified, currently practicing psychiatrists who were involved in direct patient care.
A four-page data collection instrument was mailed to the target sample with a $50 gift card to increase response. Three survey mailings were implemented at one-month intervals, each followed by a reminder postcard to increase response. All study procedures were approved by the American Psychiatric Foundation Institutional Review Board.
Using a list of ten mental health and substance use treatments and social services (no definitions were provided), participating psychiatrists were asked whether they had any problems providing or finding a referral source of care for each type of service for any individuals during the past 30 days and to indicate the number of individuals who were affected. They were also asked to indicate the number of patients whom they had treated during the last typical workweek for whom they did not have enough time during the patient visit and for whom they were not able to provide the number of visits to meet the patient’s clinical needs.
Weighted analyses were conducted using SUDAAN statistical software to adjust for the sample design, nonresponse, and physician caseload size to provide estimates that could be generalized to the target population (17). Chi square tests (for categorical variables) and Student’s t tests (for continuous variables) examined the associations between physicians’ characteristics and the types and quantity of treatment availability problems. Because of multiple comparisons, a p value of .01 was used to indicate statistical significance.

Results

Psychiatrist Sample

The psychiatrists who participated in the study were primarily male (65%), non-Hispanic whites (82%) (Table 1). A majority were general psychiatrists (75%); 21% reported specializing in child and adolescent psychiatry. Psychiatrists’ patients were most commonly treated in solo office settings (34%) and outpatient public clinics (18%). The primary sources of payment used by patients were private commercial insurance (30%) and self-pay (22%); 43% used public sources. During their last typical workweek, psychiatrists reported treating a mean of 45 patients and spending a mean of 34 hours in direct patient care.
TABLE 1. Sociodemographic, specialty, and practice characteristics of a nationwide sample of 1,099 psychiatristsa
CharacteristicN%95% CI
Age (M)56.7 56.0–57.4
Gender   
 Male7116562.0–67.8
 Female3873532.2–38.0
Race-ethnicity   
 Non-Hispanic white7768279.6–84.6
 Asian7686.6–10.2
 Hispanic4153.4–6.2
 Non-Hispanic black4043.2–5.9
 Other61.3–1.4
Region   
 West2592421.1–26.3
 South2392421.1–26.3
 Northeast2572018.2–22.8
 Midwest2001715.3–19.7
 Mid-Atlantic1441512.9–17.5
Primary psychiatry specialty   
 General8297572.6–77.9
 Child and adolescent2342119.0–24.0
 Psychoanalysis141.3–.7
 Addictions101.5–1.8
 Forensic91.5–1.9
Workload in last typical workweek (M)   
 Patients treated45.3 43.2–47.5
 Direct patient care (hours)34.3 33.4–35.2
Practice setting   
 Solo office3613433.9–39.4
 Outpatient clinic in a public hospital or freestanding facility1921815.5–19.7
 Group office2142014.2–18.4
 Outpatient clinic in a private hospital or freestanding facility8075.4–8.1
 Inpatient unit in a public hospitalb6065.3–8.0
 Inpatient unit in a private hospitalb5554.1–6.3
 Other112109.2–12.6
Patients’ main source of payment   
 Private or commercial insurancec3173026.0–29.7
 Self-payd2392223.3–27.5
 Medicaid or CHIP, including Medicaid HMOse1891815.4–18.6
 Medicare, including Medicare HMOs1551411.5–13.7
 Other government or publicf1171110.1–13.5
 No charge or uncompensated2321.8–2.7
 Other, including worker’s compensation141.8–1.6
 Don’t know2321.2–2.8
a
Ns do not always add up to 1,099 because of missing data. Percentages are weighted.
b
Includes partial hospitalization
c
Includes all private insurance, managed and nonmanaged, excluding all other categories
d
35% of self-pay patients received a receipt or bill for services for submitting directly to an insurance company or health plan for reimbursement
e
CHIP, Children’s Health Insurance Program
f
Includes U.S. Department of Veterans Affairs and state and local funding
Compared with the sampling frame (N=30,887), respondents were more likely to be non-Hispanic whites (82% versus 67% [N=20,598], p<.001) and were more likely to report specializing in child and adolescent psychiatry (21% versus 17% [N=5,329], p<.05).

Mental Health and Substance Use Treatment Availability

Thirty percent or more of the psychiatrists reported being unable to provide or find a source for clinically or socially indicated psychotherapy (36%), housing (32%), supported employment (31%), case management or assertive community treatment (ACT) (30%), and substance use treatment (30%) in the past 30 days (Table 2). Approximately one in five psychiatrists reported being unable to provide or find a source of care for inpatient treatment (21%), psychosocial rehabilitation (21%), general medical care (20%), pharmacologic treatment (19%), and child and adolescent assessment and treatment (17%) in the past 30 days. In addition, 14% of psychiatrists reported being unable to provide or find sources of care for geriatric assessment and treatment.
TABLE 2. Inability to provide or find a source for services in the past 30 days by 1,099 psychiatrists and number of patients for whom care could not be arrangeda
 Patients
ServiceN%95% CINbMean95% CI
Psychotherapy3743633.2–39.831313.610.9–16.3
Housing3243229.0–35.52759.47.4–11.4
Supported employment3043127.4–33.824712.79.7–15.8
Case management or assertive community treatment3043026.9–33.22608.46.4–10.5
Alcohol or other substance use treatment3043026.5–32.82567.25.9–8.5
Inpatient mental health treatment2042118.6–24.31795.54.0–6.9
Psychosocial rehabilitation2132118.3–23.918510.47.7–13.1
General medical care2012017.6–23.318111.89.1–14.6
Psychopharmacologic treatment or psychiatric medications2051916.4–21.717311.69.1–14.2
Child and adolescent mental health assessment and treatment1771715.0–20.21569.15.8–12.3
Geriatric mental health assessment and treatment1411412.1–17.01185.03.4–6.5
a
Percentages and means are weighted.
b
Number of psychiatrists who reported the number of patients for whom care could not be arranged
Psychiatrists reported being unable to provide or find a referral source for a mean of 2.7 (95% confidence interval=2.5–2.9) services in the past 30 days. A majority (N=813, 74%) reported being unable to provide or find a source for at least one service, 62% (N=681) for two or more services, 47% (N=517) for three or more, 34% (N=374) for four or more, and 23% (N=253) for five or more. The mean number of patients for whom psychiatrists were unable to provide or arrange for each of these services in the past 30 days ranged from 5.0 to 13.6, depending on the service (Table 2).

Ability to Spend Sufficient Time and Provide Enough Visits to Meet Patients’ Needs

Approximately half of all psychiatrists (52%) reported feeling that they did not have sufficient time to treat a patient during their last typical workweek (Table 3). Psychiatrists reported this concern for a mean of 12.8 patients, representing 28% of their patient caseloads. About 40% of all psychiatrists reported being unable to provide a sufficient number of visits to meet a patient’s clinical needs in their last typical workweek. Psychiatrists reported this concern for a mean of 10.6 patients, affecting 24% of their caseloads.
TABLE 3. Constraints on ability to provide services in the past 30 days by 1,099 psychiatrists and number of patients affected, by type of practicea
    Patients
Practice type and constraintN%95% CINbM95% CI
Solo office (N=292)      
 Not enough time during the patient visit773124.9–37.5699.05.6–12.4
 Not able to provide enough visits to meet the patient's clinical needs702519.9–31.6567.34.9–9.7
Group office (N=108)      
 Not enough time during the patient visit616150.4–70.15611.16.3–16.0
 Not able to provide enough visits to meet the patient's clinical needs363424.6–43.83110.53.7–17.4
Public outpatient clinic (N=107)      
 Not enough time during the patient visit566251.0–71.14917.511.4–23.6
 Not able to provide enough visits to meet the patient's clinical needs444635.4–56.93613.99.0–18.9
Total (N=1,099)      
 Not enough time during the patient visit4935248.7–55.544112.811.1–14.5
 Not able to provide enough visits to meet the patient's clinical needs3653734.1–40.729410.69.0–12.1
a
Practice type indicates the place where the majority of patients (≥51%) are seen. Percentages and means are weighted.
b
Number of psychiatrists who reported the number of patients for whom care could not be arranged

Psychiatrist Factors Associated With Treatment Availability Problems

Psychiatrists who reported a greater number of treatment availability problems were more likely to be younger than age 40 (versus ≥60) and less likely to be non-Hispanic white (versus other race-ethnicity) (Table 4). They were also more likely to see a majority of their patients in public outpatient clinics (versus solo practices); treat more than 44 patients per week (versus ≤44); provide more than 40 hours of direct patient care per week (versus ≤40); and primarily treat Medicaid patients (versus patients with private insurance). Time and visit constraints were commonly reported across solo, group, and public outpatient settings (Table 3). Psychiatrists who saw a majority of their patients in public outpatient clinics, treated more than 44 patients, or provided more than 40 hours of direct patient care in a typical week reported not having sufficient time nor providing sufficient visits to meet clinical needs for a greater number of patients during the last typical workweek (Table 4).
TABLE 4. Association of characteristics of psychiatrists (N=1,099) and constraints on treatment availability
CharacteristicInability to provide or arrange for servicesaInsufficient time per visitbInsufficient visitsb
NM95% CIMean diff.NM95% CIMean diff.NM95% CIMean diff.
Age            
 <401103.22.7–3.7.73**1097.33.7–10.81.581073.71.9–5.5.79
 40–491852.92.4–3.3.401726.13.9–8.3.371714.22.7–5.61.28
 50–593332.82.5–3.2.363157.25.2–9.21.493083.82.5–5.1.89
 ≥60 (reference)4552.52.2–2.7.4335.74.4–7.0 4192.92.0–3.9 
Gender            
 Female3802.72.4–3.0 3615.74.5–6.9.3473.32.3–4.3 
 Male7022.72.5–3.0.066676.75.4–8.11.026573.62.8–4.4.26
Race-ethnicity            
 Non-Hispanic white (reference)7642.52.3–2.7 7295.84.7–7.0 7123.52.7–4.3 
 Other1623.42.9–3.8.81**1549.56.2–12.83.67*1514.52.8–6.2.96
Region (states)            
 Northeastern (reference)2522.42.1–2.8 2416.14.2–8.0 2383.11.8–4.4 
 Mid-Atlantic1412.92.4–3.4.451294.93.1–6.8–1.181283.01.5–4.5–.08
 Midwestern1972.82.3–3.2.341837.24.6–9.81.081804.72.5–6.81.59
 Western2562.72.3–3.1.262487.74.6–10.71.562374.02.5–5.5.93
 Southern2372.82.5–3.1.362285.94.5–7.3–.232222.92.1–3.7–.17
Practice typec,d            
 Solo practice (reference)3702.21.9–2.4 3553.82.1–5.5 3481.91.3–2.6 
 Group practice1612.82.3–3.2.61*1537.85.1–10.53.98*1513.51.6–5.31.56
 Public outpatient clinic1793.32.8–3.71.10***1698.96.3–11.45.07***1625.33.5–7.03.36***
 Other3733.02.6–3.3.80***3526.95.4–8.43.14**3444.22.9–5.52.29***
Caseload >44 patientsc            
 Yes4482.92.7–3.2.59***4308.77.2–10.36.36***4194.73.7–5.73.25***
 No (reference)6352.42.2–2.5 5992.41.9–2.9.5861.51.1–1.8 
>40 hours of direct patient carec            
 Yes1703.42.9–3.9.89***1639.97.0–13.04.71**1595.63.5–7.62.68**
 No (reference)9092.52.3–2.7.8625.24.3–6.1.8422.92.3–3.4 
Source of payment for ≥51% of patientsc            
Private insurance (reference)2522.21.9–2.5 2435.13.7–6.5 2362.31.5–3.0 
 Self-pay2112.52.0–3.0.311992.51.6–3.3–2.64***1961.91.1–2.7–.36
 Medicare402.21.5–3.0.04384.52.1–6.8–.63401.5.2–2.9–.75
 Medicaid1363.02.5–3.5.82**1296.04.0–8.0.911283.92.2–5.51.62
 Other4443.12.8–3.3.85***4208.96.9–10.93.81**4054.93.6–6.32.66***
a
Means (weighted) indicate number of services for which care could not be provided or arranged in the past 30 days.
b
Means (weighted) indicate number of patients for whom there was insufficient time per visit or insufficient visits during the last typical workweek.
c
During the last typical workweek
d
Practice type indicates the place where the majority of patients (≥51%) are seen.
*
p≤.05, **p≤.01, ***p≤.001

Discussion

Mental Health and Substance Use Services Availability

Substantial proportions of psychiatrists reported being unable to provide or find a referral source of care for individuals needing each of the ten services examined. These findings are consistent with prior research indicating a constrained supply of mental health and substance use services (911,18,19), affecting sizable numbers of patients seeking treatment from psychiatrists. Psychiatrists’ perceptions of gaps in access to general medical care were also consistent with prior research (20). These perceptions are concerning in light of the significant excess morbidity and mortality among individuals with mental illnesses compared with the general population.
This study is notable in highlighting reports of constrained availability of even the most common mental health treatments, such as psychotherapy and medications. Although psychotherapy and medications remain first-line or adjunctive treatments for most mental illnesses (4), mounting evidence supports the superior effectiveness of a combination of modalities for a number of conditions (21). Many individuals who could benefit from combined treatments may be receiving only one type of treatment because of availability or access constraints.
Treatment availability problems may have increased since our data were collected, given that the data were collected before the ACA insurance expansions, which have increased the number of newly insured individuals seeking services. Consequently, the considerable social, economic, and human costs and burdens associated with inadequate mental health treatment access necessitate several careful considerations of health and social policy, financing, and services delivery approaches that could ameliorate the identified treatment gaps.
First, although more efficient delivery, coordination, and team-based management of care may facilitate improved access to care (22), the scope and magnitude of reported treatment availability problems in our study and in prior health care workforce studies highlight the need for increased investments in mental health, substance use, and primary care services and workforce development and training. Physician, nursing, and behavioral health workforce shortages and maldistribution problems have been well documented and are expected to worsen as a result of the aging of the U.S. population and health care workforce (19,23). Although the ACA included provisions to address the size, composition, and geographic distribution of the primary care and behavioral health workforce, these provisions included limited measures to address the shortage of psychiatrists. In addition, the extent to which these provisions will address workforce supply is unknown because they have not been fully implemented, they are temporary, and they rely on discretionary funding (24).
Second, ensuring that the full range of evidence-based treatments is covered under state Medicaid programs and HIE plan offerings will be essential for availability of and access to mental health services. It remains doubtful whether coverage for essential health benefits for persons gaining health insurance will include services not traditionally covered by commercial “benchmark plans” and only sometimes covered by Medicaid programs, such as supported employment, supported housing, psychosocial rehabilitation, and case management or ACT (3,9). The high rates of reported availability problems for evidence-based services is concerning, given that these services provide the foundation for effective, coordinated early intervention specialty care models such as the Recovery After an Initial Schizophrenia Episode model (25) for individuals with serious mental illness (26). Continued advocacy for funding and policies that facilitate access to these services is needed.
The actual levels of services covered by plans in the HIEs and by Medicaid programs, in terms of numbers of visits, inpatient days, and range of psychosocial and psychopharmacologic treatments offered, also remain uncertain. There are concerns that the services offered may not meet patients’ clinical needs, particularly for patients with severe mental illnesses, who are disproportionately represented in ACA expansion populations. In addition to concerns about quantitative coverage limits, concerns remain regarding the effect of nonquantitative treatment limits on treatment access, despite federal mental health parity protections under the ACA. Such limits include the medical management of benefits through medical necessity criteria, prior authorizations, and formulary designs, in addition to provider network and reimbursement adequacy issues (27,28).
Third, sound financing and reimbursement policies are essential to promoting appropriate delivery and organization of the levels and types of needed mental health and substance use services. Health homes, accountable care organizations, and the myriad health care delivery and payment demonstrations funded by the Centers for Medicare and Medicaid Services’ Center for Innovation hold promise for improving access to the fuller range of services needed by individuals with mental illnesses. However, the overall levels and structure of funding with health plans and health care providers, and the quality performance monitoring and financial incentive parameters implemented, will have major implications for the extent to which improved access to mental health services is realized. Sufficient levels of funding and financial incentives and protections targeted to individuals with mental health and substance use disorders will be essential to ensure availability of and access to care. This includes clinically rigorous “merit-based” or “value-based” payment methods that reflect the full range of evidence-based treatments and provider reimbursement levels and administrative terms sufficient to attract high-quality clinicians. This may prove challenging in an era of constrained resources and increasing numbers of insured individuals. Further, onerous quality-reporting demands and the risk of financial penalties might deter clinicians’ participation in these arrangements.

Psychiatrists’ Ability to Provide Sufficient Time and Visits

For a number of reasons, it would be helpful to better understand the validity and nature of psychiatrists’ perceived time and visit constraints and the potential effects of these constraints on quality and outcomes of care. These constraints may lead to insufficient patient assessments or insufficient provision of psychosocial treatments and education, resulting in poorer care. They could adversely affect best practices, such as measurement-based care and ongoing monitoring and adjustment of medications and dosing to optimize outcomes and minimize side effects (4).
Given both the medical and psychosocial complexity of many patients’ experiences with mental illnesses, it may be particularly challenging for psychiatrists to address the needs of severely ill patients during brief encounters or a limited number of encounters. New ACA models of integrated, collaborative care may help address these challenges by encouraging psychiatrists to step into leadership roles and work more closely with general medical and behavioral health providers to provide patient-centered, team-based care (29). Psychiatrists may play an increasing role in providing basic prevention and treatment for common general medical conditions, particularly for vulnerable patients with serious mental illness (30). Psychiatric patients, in particular, face constrained access to primary care services because of the shortage of primary care practitioners (31), and they frequently do not have a designated primary care provider (20). Because psychiatrists are trained in general medical and behavioral health care, they regularly evaluate and manage patients with general medical and psychiatric issues. This often requires that they spend more time with a patient compared with primary care providers, consistent with psychiatrists’ reports of patient time constraints.
Given the significantly higher treatment availability problems reported by psychiatrists who primarily treat Medicaid patients and practice in group or public clinics, exploring the nature and effect of constraints in these populations warrants more attention. Prospectively identifying attributes of patients associated with time and visit constraints through patient screening could facilitate scheduling additional time or visits as needed. Understanding how health plan coverage and management issues, including limits on the length or number of visits, are related to these constraints may be informative if there are associated effects on treatment quality and outcomes.

Strengths and Limitations of the Study

The primary strength of this study was the use of a large probability sample of U.S. psychiatrists, who represent the primary physician discipline specializing in treating mental and addictive disorders, treating an estimated 20% of individuals who receive mental health care in the United States (32). Because of their training as physicians, psychiatrists also are more likely to treat severely ill patients with complex, comorbid conditions requiring a range of pharmacologic and psychosocial treatments.
Our data are subject to psychiatrist response, recall, and social desirability biases. The exclusive reliance on physicians’ reports without external or psychometric validation of measures represents a significant limitation. Psychiatrists, particularly those who practice in solo and group office settings—who comprised half the sample—may be unaware of services available in their communities. As a result, they may overestimate treatment availability problems. Furthermore, the study’s global treatment availability measures did not distinguish between treatment availability and accessibility problems. We did not assess whether respondents tried to find services or any specific access problems encountered while doing so. In addition, even when services are available in the community, they may not be accessible to specific individuals or groups, such as low-income, uninsured, or publicly insured patients; children; non–English-speaking individuals; and active users of illicit substances.
Simple random sampling resulted in a final study sample primarily reflecting psychiatrists from more populous states, such as California, New York, Massachusetts, Florida, and Pennsylvania. Although psychiatrists from 48 states participated in the study, the sample included no psychiatrists from Delaware and West Virginia and only a few from Virginia, Wyoming, North and South Dakota, Alaska, Nevada, and Montana.

Conclusions

Findings from this study indicate that psychiatrists report significant constraints in the availability of a range of mental health, substance use, and general medical services essential for individuals with mental illnesses. Given the magnitude of these reported problems, significant enhancements of the mental health and substance use treatment workforce and services delivery infrastructure may be required in order for the ACA to realize its promise of improved health, better health care delivery, and lower costs.

Footnotes

This study was funded by the American Psychiatric Association Foundation.
The authors had complete control over all aspects of the study, including data analyses and interpretation of findings.

References

1.
Health Insurance Coverage and the Affordable Care Act. Washington, DC, US Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, May 5, 2015. Available at aspe.hhs.gov/health/reports/2015/uninsured_change/ib_uninsured_change.pdf>
2.
Affordable Care Act Expands Mental Health and Substance Use Disorder Benefits and Federal Parity Protections for 62 Million Americans. Washington, DC, US Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, Feb 2013. Available at aspe.hhs.gov/health/reports/2013/mental/rb_mental.cfm>
3.
Garfield RL, Lave JR, Donohue JM: Health reform and the scope of benefits for mental health and substance use disorder services. Psychiatric Services 61: 1081–1086, 2010
4.
American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Arlington, Va, American Psychiatric Association, 2006
5.
Mojtabai R, Cullen B, Everett A, et al: Reasons for not seeking general medical care among individuals with serious mental illness. Psychiatric Services 65:818–821, 2014
6.
Mojtabai R, Olfson M, Sampson NA, et al: Barriers to mental health treatment: results from the National Comorbidity Survey Replication. Psychological Medicine 41:1751–1761, 2010
7.
Wang PS, Berglund P, Olfson M, et al: Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62:603–613, 2005
8.
Mechanic D: Removing barriers to care among persons with psychiatric symptoms. Health Affairs 21(3):137–147, 2002
9.
Mechanic D: More people than ever before are receiving behavioral health care in the United States, but gaps and challenges remain. Health Affairs 33:1416–1424, 2014
10.
Cummings JR, Wen H, Ko M, Druss BG: Geography and the Medicaid mental health care infrastructure: implications for health care reform. JAMA Psychiatry 70:1084–1090, 2013
11.
Cunningham PJ: Beyond parity: primary care physicians’ perspective on access to mental health care. Health Affairs 3:490–501, 2009
12.
Williams ME, Latta J, Conversano P: Eliminating the wait for mental health services. Journal of Behavioral Health Services and Research 35:107–114, 2008
13.
Kessler RC, Demler O, Frank RG, et al: Prevalence and treatment of mental disorders, 1990 to 2003. New England Journal of Medicine 352:2515–2523, 2005
14.
Gallucci G, Swartz W, Hackerman F: Impact of the wait for an initial appointment on the rate of kept appointments at a mental health center. Psychiatric Services 56:344–346, 2005
15.
West JC, Wilk JE, Olfson M, et al: Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatric Services 56:283–291, 2005
16.
McGlynn EA, Asch SM, Adams J, et al: The quality of health care delivered to adults in the United States. New England Journal of Medicine 348:2635–2645, 2003
17.
LaVange LM, Shah BV, Barnwell BG, et al: SUDAAN: a comprehensive package for survey data analysis; in Data Quality Control. Edited by Liepins GE, Uppuluri VRR. New York, Marcell Dekker, 1990
18.
Harris KM, and Edlund MJ: Use of mental health care and substance abuse treatment among adults with co-occurring disorders. Psychiatric Services 56:954–959, 2005
19.
Report to Congress on the Nation’s Substance Abuse and Mental Health Workforce Issues. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2013
20.
Druss BG, Rosenheck RA: Mental disorders and access to medical care in the United States. American Journal of Psychiatry 155:1775–1777, 1998
21.
Cuijpers P, Sijbrandij M, Koole SL, et al: Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 13:56–67, 2014
22.
Barry CL, Huskamp HA: Moving beyond parity— mental health and addiction care under the ACA. New England Journal of Medicine 365:973–975, 2011
23.
Okrent D: Health Care Workforce: Future Supply vs Demand. Washington, DC, Alliance for Health Reform, 2011
24.
Heisler EJ: Physician Supply and the Affordable Care Act. Pub no 7-5700 R42029. Washington, DC, Congressional Research Service, 2013
25.
Dixon LB, Goldman HH, Bennett ME, et al: Implementing coordinated specialty care for early psychosis: the RAISE Connection Program. Psychiatric Services 66:691–698, 2015
26.
Phillips SD, Burns BJ, Edgar ER, et al: Moving assertive community treatment into standard practice. Psychiatric Services 52:771–779, 2001
27.
Bendat M: In name only? Mental health parity or illusory reform. Psychodynamic Psychiatry 42:353–375, 2014
28.
Friedman RC: Introduction to the special issue on psychotherapy, the Affordable Care Act, and mental health parity: obstacles to implementation. Psychodynamic Psychiatry 42:339–342, 2014
29.
Mechanic D: Seizing opportunities under the Affordable Care Act for transforming the mental and behavioral health system. Health Affairs 31:376–382, 2012
30.
Raney L: The evolving role of psychiatry in the era of health care reform. Psychiatric Services 64:1076–1078, 2013
31.
Bodenheimer T, Pham HH: Primary care: current problems and proposed solutions. Health Affairs 29:799–805, 2010
32.
Wang PS, Lane M, Olfson M, et al: Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Archives of General Psychiatry 62:629–640, 2005

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services

Cover: Bowl, interior, Zuni People, circa 1889. Painted terracotta MNC12330. Cité de la Ceramique, Sevres, France. Photo: Martine Beck-Coppola.

Psychiatric Services
Pages: 983 - 989
PubMed: 27079993

History

Received: 29 September 2015
Revision received: 30 November 2015
Accepted: 15 January 2016
Published online: 15 April 2016
Published in print: September 01, 2016

Authors

Details

Joyce C. West, Ph.D., M.P.P.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Diana E. Clarke, Ph.D., M.Sc.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Farifteh Firoozmand Duffy, Ph.D.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Keila D. Barber, M.H.S.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Ramin Mojtabai, M.D., Ph.D.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Eve K. Mościcki, Sc.D., M.P.H.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Kristin Kroeger Ptakowski, B.A.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.
Saul Levin, M.D., M.P.A.
Dr. West, Dr. Clarke, Dr. Duffy, Ms. Barber, and Dr. Mościcki are with the American Psychiatric Association Foundation, Arlington, Virginia (e-mail: [email protected]). Dr. Clarke is also with the Division of Research, American Psychiatric Association, Arlington, Virginia. Dr. Mojtabai is with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Ms. Kroeger Ptakowski and Dr. Levin are with the American Psychiatric Association, Arlington, Virginia.

Notes

Findings from this study were presented in part at the Academy Health Annual Research Meeting, Minneapolis, Minnesota, June 13–16, 2015.

Funding Information

American Psychiatric Association Foundation: American Psychiatric Association Foundation New In
Dr. West and Dr. Duffy are working on studies funded through the American Psychiatric Association Foundation by Forest Laboratories, Lundbeck, and Takeda Pharmaceuticals. The other authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share